Read on Twitter
On #DayofImmunology, I’m looking back at an exciting step in the dissemination of scientific research for the benefit of the #immunology community: the launch of the 1st #OpenAccess journal of @britsocimm: @IMTadvances. Why now? Why #immunotherapy? My 1st #tweetorial 1/n
In #cancer, #autoimmune disease & #allergy, many conventional treatments have been replaced with #immunotherapy drugs. More diseases will soon reveal immunological targets. But what does the future look like? Dr Kees Melief ponders this question here https://buff.ly/2ZtvN1l 2/n
As #immunotherapy becomes mainstream, the massive growth in the drug market will help to pull through novel agents & therapeutic approaches from the lab into #clinicaltrials. This will inevitably drive research into mechanism of action 3/n
What can we offer the exploding field of #immunotherapy with @IMTadvances? 1st, we span the translational pipeline from discovery to clinical trials. Importantly, we also encourage experimental medicine &first-in-human studies where they contribute to immune-mechanistic insight 4
2nd, @IMTadvances is truly interdisciplinary. The curious mind can gain important mechanistic insight by combining disciplines at all stages in the translational pipeline, so studies involving engineering, mathematics, computer science, chemistry & physics are encouraged 5/n
3rd, our #OpenAccess platform helps to bring #immunotherapy content to a diverse audience, including doctors, patients & policymakers. For example, our current issue features an article on the translation of #CellTherapy from a regulators’ perspective https://buff.ly/3kfuRrj 6/n
Lastly, I’m delighted to be working with 6 Editors worldwide to ensure @IMTadvances content is global: Stephanie Dougan @DanaFarber, Adriana Bonomo @fiocruz, @MarianneBoes, Stefan Barth @UCTIDM, @TaoDong14 & Menno van Zelm @ImmunologyMU 7/n
Launching a new journal is very exciting…at #Immunotherapy Advances we like giving experts the opportunity to discuss the very latest #clinicaltrials activity in their area, so we have established a special TrialsWatch section. (More info https://buff.ly/2R90Rm9 ) 8/n
I’d like to take this opportunity to thank the @britsocimm Affinity Groups – you have been integral in the development of the TrialsWatch series, providing insights into the field and asking key researchers to contribute. Take a look at great eg’s here: https://buff.ly/2QyunSx 9/
Finally, as an official journal of @britsocimm, #Immunotherapy Advances has an excellent pedigree. Profits from the journal are reinvested back into the Society – I hope you will join me in supporting the BSI to ensure that @IMTadvances becomes a leading journal in the field. 10/
